Anthracycline chemotherapy, vascular dysfunction and cognitive impairment: burgeoning topics and future directions

Anthracyclines, chemotherapeutic agents used to treat common forms of cancer, increase cardiovascular (CV) complications, thereby necessitating research regarding interventions to improve the health of cancer survivors. Vascular dysfunction, which is induced by anthracycline chemotherapy, is an established antecedent to overt CV diseases. Potential treatment options for ameliorating vascular dysfunction have largely been understudied. Furthermore, patients treated with anthracyclines have impaired cognitive function and vascular dysfunction is an independent risk factor for the development of mild cognitive impairment. Here, we will focus on: anthracycline chemotherapy associated CV diseases risk; how targeting mechanisms underlying vascular dysfunction may be a means to improve both CV and cognitive health; and research gaps and potential future directions for the field of cardio-oncology. Cancer and cardiovascular diseases are highly prevalent in the USA and are inter-related issues. Drugs that are used to treat common cancers effectively destroy harmful cancer cells but negatively impact the function of the heart and blood vessels. Cancer patients treated with these drugs are at a high risk of developing problems within the blood vessels that prevent the vessels from dilating properly. Cancer treatments are also associated with impaired memory and brain function later in life. It is important to understand how and why these cancer treatments increase the risk of developing cardiovascular diseases and cognitive impairment. Current research is examining the mechanisms (i.e., potential therapeutic targets) underlying the negative effects of these drugs with the goal of developing interventions and additional treatments to improve the quality of life of cancer survivors.